279 related articles for article (PubMed ID: 24002090)
21. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
McCormick AL; Parry CM; Crombe A; Goodall RL; Gupta RK; Kaleebu P; Kityo C; Chirara M; Towers GJ; Pillay D
Antimicrob Agents Chemother; 2011 Apr; 55(4):1806-9. PubMed ID: 21282419
[TBL] [Abstract][Full Text] [Related]
22. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
Basson AE; Rhee SY; Parry CM; El-Khatib Z; Charalambous S; De Oliveira T; Pillay D; Hoffmann C; Katzenstein D; Shafer RW; Morris L
Antimicrob Agents Chemother; 2015 Feb; 59(2):960-71. PubMed ID: 25421485
[TBL] [Abstract][Full Text] [Related]
23. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
[TBL] [Abstract][Full Text] [Related]
24. Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA).
Rossotti R; Fonte L; Meini G; Maggiolo F; Zazzi M; Rusconi S;
J Med Virol; 2014 Sep; 86(9):1459-66. PubMed ID: 24838991
[TBL] [Abstract][Full Text] [Related]
25. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
26. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
Fourati S; Malet I; Lambert S; Soulie C; Wirden M; Flandre P; Fofana DB; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2012 Aug; 26(13):1619-24. PubMed ID: 22695298
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
Asahchop EL; Oliveira M; Wainberg MA; Brenner BG; Moisi D; Toni Td; Tremblay CL
Antimicrob Agents Chemother; 2011 Feb; 55(2):600-7. PubMed ID: 21135184
[TBL] [Abstract][Full Text] [Related]
28. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
[TBL] [Abstract][Full Text] [Related]
29. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
30. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
31. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
32. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
[TBL] [Abstract][Full Text] [Related]
34. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
Kulkarni R; Feng JY; Miller MD; White KL
Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
[TBL] [Abstract][Full Text] [Related]
35. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
36. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
37. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Reuman EC; Rhee SY; Holmes SP; Shafer RW
J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
[TBL] [Abstract][Full Text] [Related]
38. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.
Huang W; Gamarnik A; Limoli K; Petropoulos CJ; Whitcomb JM
J Virol; 2003 Jan; 77(2):1512-23. PubMed ID: 12502865
[TBL] [Abstract][Full Text] [Related]
39. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
Barnard JP; Huber KD; Sluis-Cremer N
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
